Drug Search Results
More Filters [+]

XL-999

Alternative Names: xl-999, xl999, xl 999
Latest Update: 2014-10-21
Latest Update Note: Clinical Trial Update

Product Description

XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00491699)

Mechanisms of Action: SSK Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Symphony Evolution
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for XL-999

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Multiple Myeloma|Renal Cell Carcinoma|Colorectal Cancer|Ovarian Cancer|Non-Small-Cell Lung Cancer|Acute Myeloid Leukemia

Phase 1: Oncology Unspecified|Oncology Solid Tumor Unspecified|Non-Small-Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTRC 10-08

N/A

No longer available

Oncology Unspecified

2012-06-01

XL999-900

P1

Completed

Oncology Unspecified

2010-05-01

XL999-001

P1

Completed

Oncology Solid Tumor Unspecified

2008-09-01

XL999-002

P1

Terminated

Non-Small-Cell Lung Cancer

2008-01-01

Recent News Events

Date

Type

Title